טוען...
Improved power for TB Phase IIa trials using a model-based pharmacokinetic–pharmacodynamic approach compared with commonly used analysis methods
Background: The demand for new anti-TB drugs is high, but development programmes are long and costly. Consequently there is a need for new strategies capable of accelerating this process. Objectives: To explore the power to find statistically significant drug effects using a model-based pharmacokine...
שמור ב:
| הוצא לאור ב: | J Antimicrob Chemother |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Oxford University Press
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5890728/ https://ncbi.nlm.nih.gov/pubmed/28520930 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkx129 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|